A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia

Kami Maddocks, Amy S. Ruppert, Rebekah Browning, Jeffrey Jones, Joseph Flynn, Cheryl Kefauver, Yue Gao, Yao Jiang, Darlene M. Rozewski, Ming Poi, Mitch A. Phelps, Erica Harper, Amy J. Johnson, John C. Byrd, Leslie A. Andritsos

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Adequate dosing of lenalidomide in Chronic Lymphocytic Leukemia (CLL) remains unclear. This study determined maximum tolerated dose (MTD) in relapsed CLL patients (Cohort A) and patients achieving a partial response (PR) or better to recent therapy (Cohort B). Thirty-seven patients were enrolled. MTD was 2.5. mg followed by 5.0. mg continuous. In Cohort A, tumor flare grade 1-2 occurred in 15 patients (50%) and grade 3 in 1 patient (3%). Cohort A had 19 of 23 evaluable (83%) patients, 4 PR (17%) and 15 (65%) stable disease (SD), Cohort B had 6 of 7 patients (86%) with SD. Despite overall response rate not being high, many patients remained on therapy several months with SD.

Original languageEnglish
Pages (from-to)1025
Number of pages1
JournalLeukemia Research
Volume38
Issue number9
DOIs
StatePublished - Sep 2014

Keywords

  • Chronic Lymphocytic Leukemia
  • Lenalidomide
  • Maintenance
  • Relapse
  • Tumor flare

Fingerprint

Dive into the research topics of 'A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this